285 related articles for article (PubMed ID: 29676944)
1. Integration of Clinical Variables for the Prediction of Late Distant Recurrence in Patients With Estrogen Receptor-Positive Breast Cancer Treated With 5 Years of Endocrine Therapy: CTS5.
Dowsett M; Sestak I; Regan MM; Dodson A; Viale G; Thürlimann B; Colleoni M; Cuzick J
J Clin Oncol; 2018 Jul; 36(19):1941-1948. PubMed ID: 29676944
[TBL] [Abstract][Full Text] [Related]
2. Overestimation of Late Distant Recurrences in High-Risk Patients With ER-Positive Breast Cancer: Validity and Accuracy of the CTS5 Risk Score in the TEAM and IDEAL Trials.
Noordhoek I; Blok EJ; Meershoek-Klein Kranenbarg E; Putter H; Duijm-de Carpentier M; Rutgers EJT; Seynaeve C; Bartlett JMS; Vannetzel JM; Rea DW; Hasenburg A; Paridaens R; Markopoulos CJ; Hozumi Y; Portielje JEA; Kroep JR; van de Velde CJH; Liefers GJ
J Clin Oncol; 2020 Oct; 38(28):3273-3281. PubMed ID: 32706636
[TBL] [Abstract][Full Text] [Related]
3. Clinical validity of clinical treatment score 5 (CTS5) for estimating risk of late recurrence in unselected, non-trial patients with early oestrogen receptor-positive breast cancer.
Richman J; Ring A; Dowsett M; Sestak I
Breast Cancer Res Treat; 2021 Feb; 186(1):115-123. PubMed ID: 33222093
[TBL] [Abstract][Full Text] [Related]
4. The clinical usefulness of the CTS5 in the prediction of late distant recurrence in postmenopausal women with estrogen receptor-positive early breast cancer.
Tajiri W; Ijichi H; Takizawa K; Koi Y; Masuda T; Ueo H; Koga C; Nakamura Y; Taguchi K; Okamoto M; Tokunaga E
Breast Cancer; 2021 Jan; 28(1):67-74. PubMed ID: 32601800
[TBL] [Abstract][Full Text] [Related]
5. Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population.
Sgroi DC; Sestak I; Cuzick J; Zhang Y; Schnabel CA; Schroeder B; Erlander MG; Dunbier A; Sidhu K; Lopez-Knowles E; Goss PE; Dowsett M
Lancet Oncol; 2013 Oct; 14(11):1067-1076. PubMed ID: 24035531
[TBL] [Abstract][Full Text] [Related]
6. Prediction of late distant recurrence after 5 years of endocrine treatment: a combined analysis of patients from the Austrian breast and colorectal cancer study group 8 and arimidex, tamoxifen alone or in combination randomized trials using the PAM50 risk of recurrence score.
Sestak I; Cuzick J; Dowsett M; Lopez-Knowles E; Filipits M; Dubsky P; Cowens JW; Ferree S; Schaper C; Fesl C; Gnant M
J Clin Oncol; 2015 Mar; 33(8):916-22. PubMed ID: 25332252
[TBL] [Abstract][Full Text] [Related]
7. Validation of CTS5 on a Retrospective Cohort of Real-Life Pre- and Postmenopausal Patients Diagnosed With Estrogen Receptor-Positive Breast Cancers: Is It Prognostic?
Villasco A; Agnelli F; D'Alonzo M; Accomasso F; Sismondi P; Biglia N
Clin Breast Cancer; 2021 Feb; 21(1):e53-e62. PubMed ID: 32703705
[TBL] [Abstract][Full Text] [Related]
8. Identifying clinically relevant prognostic subgroups of postmenopausal women with node-positive hormone receptor-positive early-stage breast cancer treated with endocrine therapy: a combined analysis of ABCSG-8 and ATAC using the PAM50 risk of recurrence score and intrinsic subtype.
Gnant M; Sestak I; Filipits M; Dowsett M; Balic M; Lopez-Knowles E; Greil R; Dubsky P; Stoeger H; Rudas M; Jakesz R; Ferree S; Cowens JW; Nielsen T; Schaper C; Fesl C; Cuzick J
Ann Oncol; 2015 Aug; 26(8):1685-91. PubMed ID: 25935792
[TBL] [Abstract][Full Text] [Related]
9. Validation of the OncoMasTR Risk Score in Estrogen Receptor-Positive/HER2-Negative Patients: A TransATAC study.
Buus R; Sestak I; Barron S; Loughman T; Fender B; Ruiz CL; Dynoodt P; Wang CA; O'Leary D; Gallagher WM; Dowsett M; Cuzick J
Clin Cancer Res; 2020 Feb; 26(3):623-631. PubMed ID: 31641007
[TBL] [Abstract][Full Text] [Related]
10. Validation of CTS5 Model in Large-scale Breast Cancer Population and Combination of CTS5 and Ki-67 Status to Develop a Novel Nomogram for Prognosis Prediction.
Ning L; Liu Y; He X; Han R; Xin Y; Zhao J; Liu X
Am J Clin Oncol; 2024 May; 47(5):228-238. PubMed ID: 38131531
[TBL] [Abstract][Full Text] [Related]
11. Clinical Treatment Score post-5 years as a predictor of late distant recurrence in hormone receptor-positive breast cancer: systematic review and meta-analysis.
Shrestha A; Cullinane C; Evoy D; Geraghty J; Rothwell J; Walshe J; McCartan D; McDermott E; Prichard R
Br J Surg; 2022 Apr; 109(5):411-417. PubMed ID: 35194632
[TBL] [Abstract][Full Text] [Related]
12. Validation of Clinical Treatment Score post-5 years (CTS5) risk stratification in premenopausal breast cancer patients and Ki-67 labelling index.
Lee J; Cha C; Ahn SG; Kim D; Park S; Bae SJ; Kim J; Park HS; Park S; Kim SI; Park BW; Jeong J
Sci Rep; 2020 Oct; 10(1):16850. PubMed ID: 33033359
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the ability of the Clinical Treatment Score at 5 years (CTS5) compared to other risk stratification methods to predict the response to an extended endocrine therapy in breast cancer patients.
Villasco A; Accomasso F; D'Alonzo M; Agnelli F; Sismondi P; Biglia N
Breast Cancer; 2021 Sep; 28(5):1131-1140. PubMed ID: 33939116
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the Performance of 6 Prognostic Signatures for Estrogen Receptor-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.
Sestak I; Buus R; Cuzick J; Dubsky P; Kronenwett R; Denkert C; Ferree S; Sgroi D; Schnabel C; Baehner FL; Mallon E; Dowsett M
JAMA Oncol; 2018 Apr; 4(4):545-553. PubMed ID: 29450494
[TBL] [Abstract][Full Text] [Related]
15. Is the CTS5 a helpful decision-making tool in the extended adjuvant therapy setting?
Wimmer K; Hlauschek D; Balic M; Pfeiler G; Greil R; Singer CF; Halper S; Steger G; Suppan C; Gampenrieder SP; Helfgott R; Egle D; Filipits M; Jakesz R; Sölkner L; Fesl C; Gnant M; Fitzal F
Breast Cancer Res Treat; 2024 Jun; 205(2):227-239. PubMed ID: 38273214
[TBL] [Abstract][Full Text] [Related]
16. Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study.
Dowsett M; Cuzick J; Wale C; Forbes J; Mallon EA; Salter J; Quinn E; Dunbier A; Baum M; Buzdar A; Howell A; Bugarini R; Baehner FL; Shak S
J Clin Oncol; 2010 Apr; 28(11):1829-34. PubMed ID: 20212256
[TBL] [Abstract][Full Text] [Related]
17. The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2- breast cancer patients.
Dubsky P; Brase JC; Jakesz R; Rudas M; Singer CF; Greil R; Dietze O; Luisser I; Klug E; Sedivy R; Bachner M; Mayr D; Schmidt M; Gehrmann MC; Petry C; Weber KE; Fisch K; Kronenwett R; Gnant M; Filipits M;
Br J Cancer; 2013 Dec; 109(12):2959-64. PubMed ID: 24157828
[TBL] [Abstract][Full Text] [Related]
18. Effects of cyclin D1 gene amplification and protein expression on time to recurrence in postmenopausal breast cancer patients treated with anastrozole or tamoxifen: a TransATAC study.
Lundgren K; Brown M; Pineda S; Cuzick J; Salter J; Zabaglo L; Howell A; Dowsett M; Landberg G;
Breast Cancer Res; 2012 Apr; 14(2):R57. PubMed ID: 22475046
[TBL] [Abstract][Full Text] [Related]
19. A Novel Breast Cancer Index for Prediction of Distant Recurrence in HR
Zhang Y; Schroeder BE; Jerevall PL; Ly A; Nolan H; Schnabel CA; Sgroi DC
Clin Cancer Res; 2017 Dec; 23(23):7217-7224. PubMed ID: 28939745
[No Abstract] [Full Text] [Related]
20. Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone.
Gnant M; Filipits M; Greil R; Stoeger H; Rudas M; Bago-Horvath Z; Mlineritsch B; Kwasny W; Knauer M; Singer C; Jakesz R; Dubsky P; Fitzal F; Bartsch R; Steger G; Balic M; Ressler S; Cowens JW; Storhoff J; Ferree S; Schaper C; Liu S; Fesl C; Nielsen TO;
Ann Oncol; 2014 Feb; 25(2):339-45. PubMed ID: 24347518
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
